Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 Patients
- 1 July 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 24 (7) , 1003-1007
- https://doi.org/10.1089/aid.2007.0303
Abstract
Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.Keywords
This publication has 14 references indexed in Scilit:
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistanceCurrent Medical Research and Opinion, 2006
- Effects of drug resistance on viral load in patients failing antiretroviral therapyJournal of Medical Virology, 2006
- HIV-1 Integrase Inhibitors: A Decade of Research and Two Drugs in Clinical TrialCurrent Topics in Medicinal Chemistry, 2004
- HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1AIDS, 2004
- Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patientsAIDS, 2002
- Natural selection results in conservation of HIV-1 integrase activity despite sequence variabilityAIDS, 2001
- Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding.Proceedings of the National Academy of Sciences, 1993
- Mutational analysis of the integrase protein of human immunodeficiency virus type 2.Proceedings of the National Academy of Sciences, 1992
- Integration of human immunodeficiency virus type 1 DNA in vitro.Proceedings of the National Academy of Sciences, 1990